Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Circulating immune complexes and complement in the course of multiple sclerosis.

H Jans, A Heltberg, N E Raun

    Acta Neurologica Scandinavica
    |October 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The risk of type 2-diabetes among persons with intellectual disability: a Danish population-based matched cohort study.

    Journal of intellectual disability research : JIDR·2024
    Same author

    Sci-Fri PM: Planning-02: MRI-based radiation treatment planning for an MRI-linac system.

    Medical physics·2017
    Same author

    Medical care and organisation at the 2012 Roskilde Music Festival: a prospective observational study.

    Acta anaesthesiologica Scandinavica·2014
    Same author

    Impact of a physician-staffed helicopter on a regional trauma system: a prospective, controlled, observational study.

    Acta anaesthesiologica Scandinavica·2013
    Same author

    Shape-controlled synthesis of NIR absorbing branched gold nanoparticles and morphology stabilization with alkanethiols.

    Nanotechnology·2010
    Same author

    Impact of pre-concentration to covalently biofunctionalize suspended nanoparticles.

    Nanotechnology·2010

    This study investigated the humoral immune response in multiple sclerosis (MS) patients, finding circulating immune complexes (CIC) frequently present and linked to disease progression. Heterophilic antibodies (HPA) correlated with MS attacks.

    Area of Science:

    • Immunology
    • Neurology
    • Clinical Medicine

    Background:

    • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
    • Understanding the humoral immune response in MS is crucial for developing effective treatments.
    • Previous research has indicated potential roles for immune complexes and antibodies in MS pathogenesis.

    Purpose of the Study:

    • To evaluate the dynamics of the humoral immune response in patients with multiple sclerosis over one year.
    • To investigate the relationship between immune markers, neurological deficit, and disease activity in MS.
    • To assess the correlation of circulating immune complexes (CIC) and heterophilic antibodies (HPA) with clinical outcomes in MS.

    Main Methods:

    • Longitudinal study of 21 MS patients over 1 year with regular clinical and laboratory assessments.

    Related Experiment Videos

  • Measurement of total neurological deficit (TND).
  • Laboratory analysis of complement profiles (C3, C4), circulating immune complexes (CIC), and heterophilic antibodies (HPA).

    • Main Results:

    • Circulating immune complexes (CIC) were detected in 58.7% of investigations, often with C3 and C4 activation.
    • No significant difference in mean complement levels between MS patients and healthy controls.
    • Negative regression of TND on prior C4 and concurrent C3 levels; positive regression of subsequent CIC on TND.
    • Occurrence of MS attacks correlated with HPA development, but CIC presence did not correlate with clinical MS type.

    Conclusions:

    • The humoral immune response, particularly CIC and HPA, plays a dynamic role in multiple sclerosis.
    • CIC and complement activation are associated with neurological deficit progression in MS.
    • HPA may serve as a marker for MS exacerbations, warranting further investigation.